| Dear Fellow Investor, Studies find that multiple purchases by C-level executives signal strong annualized returns. Mineralys Therapeutics, Inc. – SYM: MLYS
Recent Price: $18.00
Insider Action: 5 insiders buy $44 mil in shares
Description: Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. If you are worried about your investment portfolio… drop everything and watch this demo immediately. It reveals how just ONE trade could make you $1,000 (or more) every month, even as stocks, cryptocurrencies, and the economy keep crashing. In the next few minutes, this demo will walk you through step-by-step (nothing held back) so you can start using it today. Click here now to watch the demo. Fidelity National Information Services, Inc. – SYM: FIS
Recent Price: $64.82
Insider Action: 8 insiders buy $1.2 mil in shares
Description: Fidelity National Information Services, Inc. is a provider of technology solutions for merchants, banks, and capital markets firms globally. The Company’s segments include Merchant Solutions (Merchant), Banking Solutions (Banking) and Capital Market Solutions (Capital Markets). The Merchant segment is focused on serving merchants of all sizes globally, enabling them to accept, authorize and settle electronic payment transactions. The Banking segment is focused on serving financial institutions of all sizes with core processing software, transaction processing software and complementary applications and services, many of which interact directly with processing software. The Banking segment sells its solutions and services on either a bundled or stand-alone basis. The Capital Markets segment is focused on serving global financial services clients with a broad array of buy- and sell-side solutions. He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Marketwatch called him "The Advisor Who Recommended Google Before Anyone Else." Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2023. Click here to download your free copy. OneWater Marine Inc. – SYM: ONEW
Recent Price: $28.81
Insider Action: 3 insiders buy $333K in shares
Description: OneWater Marine Inc. is a holding company and sole managing member of One Water Marine Holdings, LLC. It is a marine retailer in the United States with 100 retail locations, 12 distribution centers/warehouses and multiple online marketplaces in 20 different states. Its segments include Dealerships and Distribution. The Dealership segment engages in the sale of new and pre-owned boats, arranges financing and insurance products, performs repair and maintenance services, offers marine related parts and accessories and offers slip and storage accommodations in certain locations. The Distribution segment engages in the manufacturing, assembly, and distribution primarily of marine-related products to distributors, big-box retailers and online retailers through a network of warehouses and distribution centers. It offers a range of branded parts and accessories, including jack plates, rigging parts, plumbing components, storage systems, and appearance, cleaning, and maintenance products. Were you holding any tech stocks in 2022? If so, you probably had a pretty bad year. But what if I told you there was a way to not only avoid the worst of those crashes, but also make gains of over 250%? It's all thanks to a revolutionary new investment system called the Stock Genome Project. This groundbreaking software sequences the genetic code of over 50,000 stocks and funds and tells you if any stock is in buy, hold or sell mode based on it's unique DNA. Click here to learn more. Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 800-851-1965. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance.
Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.
Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.
To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE.
The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.
Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance.
No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer.
To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time
without notice.
The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information.
The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets
Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. |
Post a Comment
Post a Comment